The merger with Ireland's Elan Corporation is the topic of a special shareholders meeting for Perrigo next month. Anyone who owns stock in the Allegan-based company as of October 15 is eligible to attend and vote on the deal. Perrigo announced plans to merge with Elan in July and then reincorporate the company in Dublin to take advantage of the corporate tax rate of 12.5% in Ireland compared to the 30% in the U.S. Current executive offices will not be relocated, and the company does not anticipate any job cuts in west Michigan from the deal. It's expected to receive regulatory approval and close by the end of the year. Elan is a biotech firm that has pioneered a treatment for Multiple Sclerosis.
WebReadyTM Powered by WireReady® NSI